Repligen (RGEN) EBITDA (2010 - 2026)

Repligen (RGEN) has reported EBITDA for 17 consecutive years, with $14.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 0.58% year-over-year to $14.0 million in Q2 2026; TTM through Jun 2026 was $64.6 million, a 370.8% increase from a year earlier, with the FY2025 full-year figure at $55.2 million, up 257.11% from the prior year.
• EBITDA was $14.0 million for Q2 2026 at Repligen, down from $15.9 million in the prior quarter.
• Over five years, EBITDA peaked at $63.2 million in Q2 2022 and troughed at -$36.5 million in Q4 2024.
• A 5-year average of $17.9 million and a median of $13.9 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 469.71% in 2024 and jumped 314.82% in 2025, its largest moves.
• Over 5 years, EBITDA stood at $48.8 million in 2022, then plunged by 79.78% to $9.9 million in 2023, then sank by 469.71% to -$36.5 million in 2024, then surged by 148.95% to $17.9 million in 2025, then decreased by 21.78% to $14.0 million in 2026.
• The last three EBITDA figures came in at $14.0 million (Q2 2026), $15.9 million (Q1 2026), and $17.9 million (Q4 2025), per Business Quant data.